CTOs on the Move

MBX Biosciences

www.mbxbio.com

 
MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.mbxbio.com
  • 11711 N. Meridian Street Suite 310
    Carmel, IN USA 46032
  • Phone: N/A

Executives

Name Title Contact Details

Funding

MBX Biosciences raised $34.6M on 07/27/2020

Similar Companies

Affiliated Dermatologists, S.C.

Affiliated Dermatologists, S.C. is a Brookfield, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NextImage Medical

NextImage Medical, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Iovance Biotherapeutics

Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California.

Artiva Biotherapeutics

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva Biotherapeutics was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, our mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva`s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.

CiVi Biopharma

CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company`s research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi`s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.